Literature DB >> 22391726

11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline.

Marina Orevi1, Martine Klein, Eyal Mishani, Roland Chisin, Nanette Freedman, Ofer N Gofrit.   

Abstract

OBJECTIVE: We present a first study of the use of 11C-acetate (ACET) positron emission tomography (PET)/computed tomography (CT) in bladder urothelial carcinoma (UC) and an intraindividual comparison with 11C-choline (CHOL) PET/CT.
METHODS: Fourteen patients with biopsy-proven UC (11 T2, 3 T1 refractory to treatment) were prospectively evaluated before radical cystectomy and excision of pelvic lymph nodes (LNs), with ACET and CHOL PET/CT scans performed within 1 week. Image acquisition started 5 minutes after intravenous injection of 12 to 14 mCi for both tracers. Standardized uptake values (SUVs) and tumor-to-background ratios (TBR) were calculated for all tumor and nodal findings and correlated with histopathology and follow-up.
RESULTS: ACET and CHOL were taken up in all UCs, involved LNs, and prostate pathology. SUVs were on average slightly, nonsignificantly higher for CHOL uptake (SUV) in UCs and significantly higher for ACET in LNs. TBR was nonsignificantly higher with CHOL for UC and significantly higher for LNs.
CONCLUSIONS: In this preliminary series, 11C-ACET and 11C-CHOL PET/CT showed equivalent results in the preoperative evaluation of UC. Both tracers have the potential to contribute to selecting patients who would benefit from combined treatment--neoadjuvant chemotherapy and surgery--by identifying pathologic LNs or from surgery only, thanks to their high negative predictive value for LN involvement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391726     DOI: 10.1097/RLU.0b013e31824786e7

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  14 in total

Review 1.  Radiopharmaceuticals as probes to characterize tumour tissue.

Authors:  Israt S Alam; Mubarik A Arshad; Quang-Dé Nguyen; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

2.  Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis.

Authors:  Jack Crozier; Nathan Papa; Marlon Perera; Brian Ngo; Damien Bolton; Shomik Sengupta; Nathan Lawrentschuk
Journal:  World J Urol       Date:  2018-08-17       Impact factor: 4.226

3.  [Positron-emission tomography in urooncology].

Authors:  T Maurer; H Kübler; J E Gschwend; M Eiber
Journal:  Urologe A       Date:  2015-07       Impact factor: 0.639

Review 4.  PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  PET Clin       Date:  2015-04-24

5.  [Functional imaging in bladder cancer].

Authors:  T Maurer; T Horn; A J Beer; M Eiber; J E Gschwend
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

6.  Application of (18)F-FDG PET/CT imaging in diagnosing bladder tumor metastasis lesions.

Authors:  Yang Li; Zhong-Qing Yang; Hui Ye; Lin Qi; Jun-Wu Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

7.  First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.

Authors:  Franz Buchegger; Valentina Garibotto; Thomas Zilli; Laurent Allainmat; Sandra Jorcano; Hansjörg Vees; Olivier Rager; Charles Steiner; Habib Zaidi; Yann Seimbille; Osman Ratib; Raymond Miralbell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-09       Impact factor: 9.236

Review 8.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

9.  FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.

Authors:  E E Fransen van de Putte; E Vegt; L S Mertens; A Bruining; K Hendricksen; M S van der Heijden; S Horenblas; B W G van Rhijn
Journal:  Int Urol Nephrol       Date:  2017-07-03       Impact factor: 2.370

Review 10.  [Molecular multimodal hybrid imaging in prostate and bladder cancer].

Authors:  T Maurer; M Eiber; B J Krause
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.